Cargando…
Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study
INTRODUCTION: To examine the long‐term efficacy and safety of duloxetine in the treatment of Japanese patients with diabetic neuropathic pain, we carried out a 52‐week, randomized, open‐label extension of a 12‐week, double‐blind, placebo‐controlled study. MATERIALS AND METHODS: Japanese adults with...
Autores principales: | Yasuda, Hitoshi, Hotta, Nigishi, Kasuga, Masato, Kashiwagi, Atsunori, Kawamori, Ryuzo, Yamada, Tadaaki, Baba, Yuko, Alev, Levent, Nakajo, Ko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718094/ https://www.ncbi.nlm.nih.gov/pubmed/26816607 http://dx.doi.org/10.1111/jdi.12361 |
Ejemplares similares
-
Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan
por: Yasuda, Hitoshi, et al.
Publicado: (2011) -
Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials
por: Alev, Levent, et al.
Publicado: (2017) -
Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
por: Skljarevski, Vladimir, et al.
Publicado: (2012) -
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006) -
Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, doubleblind, noninferiority comparative study with pregabalin
por: Enomoto, Hiroyuki, et al.
Publicado: (2018)